Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2621-2640 of 3,900 trials

Alzheimer's Dementia: ITI-1284 for Agitation

We are studying whether ITI-1284 can help reduce agitation in patients with Alzheimer's dementia compared to a placebo. The trial will also assess the safety and tolerability of this new treatment.

Alzheimer's Disease3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Rett Syndrome: Leriglitazone Study for Children

We are testing the safety and effects of a new medication, leriglitazone, in children with Rett Syndrome. The study aims to understand its impact on development and caregiver challenges.

Rett Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPediatrics

Irritable Bowel Syndrome: GSL-01-001 Treatment

We are testing a new oral medication for people with Irritable Bowel Syndrome to see if it helps control symptoms like pain and bloating. The study also aims to evaluate its safety and impact on quality of life.

Irritable Bowel Syndrome (IBS)6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Chronic Lymphocytic Leukemia: Venetoclax with Ibrutinib and Rituximab

We are studying a combination of venetoclax, rituximab, and ibrutinib for treatment-naïve patients with chronic lymphocytic leukemia. The aim is to see if this approach can lead to undetectable minimal residual disease.

Chronic Lymphocytic Leukaemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Leukemia: Venetoclax with Stem Cell Transplant

We are evaluating the safety and effectiveness of Venetoclax combined with standard treatment for patients with high-risk MDS, CMML, or sAML undergoing stem cell transplantation. This study aims to improve outcomes and reduce complications during treatment.

Leukemia>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Painful Diabetic Peripheral Neuropathy: VX-993 Study

We are evaluating a new oral medication, VX-993, for people with pain from diabetic peripheral neuropathy. The study aims to determine if it effectively reduces pain and is safe to use.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyNeurology

Ulcerative Colitis in Kids: Risankizumab Study

We are evaluating how well Risankizumab works and its safety for children aged 2 to under 18 with moderately to severely active ulcerative colitis. This study will help us understand how the drug is processed in their bodies.

Ulcerative Colitis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyPediatrics

Ovarian Cancer: HIPEC Treatment Study

We are studying the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with standard care for ovarian cancer patients. This trial aims to see if HIPEC improves survival and quality of life compared to standard treatments alone.

Ovarian and Fallopian Tube CancerConfirmation phase (III)No PlaceboStandard MedicinesOncology

NPM1-Mutated Acute Myeloid Leukemia: Eltanexor Study

We are evaluating a new drug called eltanexor for patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The study aims to see if it is safe and effective in treating this condition.

Acute Myeloid LeukemiaEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Antibiotic Treatment for Critically Ill Patients

We are studying whether a short course of high-dose antibiotics is as effective as standard treatment for critically ill patients with pneumonia, intra-abdominal infections, or bloodstream infections. This research may help reduce antibiotic use while maintaining patient safety.

Pneumonia and Bacterial Infections>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Juvenile Idiopathic Arthritis: Early Drug Withdrawal Study

We are exploring whether stopping medication early is safe and effective for children with juvenile idiopathic arthritis in remission. This study also aims to identify new biomarkers that may help predict flare-ups after treatment withdrawal.

Juvenile Idiopathic Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPediatricsRheumatology

Gout Treatment: Prednisolone vs. Colchicine

We are comparing two medications for treating acute gout attacks to see which one provides better pain relief and improves joint function. This study aims to help patients find more effective treatment options.

Gout>2 yearsMonitoring phase (IV)Standard MedicinesRheumatology

Inflammatory Bowel Disease: Vedolizumab Dose Reduction Study

We are studying whether patients with inflammatory bowel disease can safely lower their dose of vedolizumab. This trial will help us understand the effects on health, costs, and quality of life.

Inflammatory Bowel Disease1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Advanced Solid Tumors: OMTX705 Treatment

We are testing a new antibody-drug conjugate for patients with advanced solid tumors. The study looks at its effects alone and in combination with another treatment to see how well it works.

Tumors Expressing Fibroblast Activation Protein (FAP)>2 yearsSafety phase (I)Oncology

Lupus Nephritis: MSV-ALLO® Treatment Study

We are testing a new cell therapy for lupus nephritis to see if it helps patients achieve remission. The study compares this treatment to a placebo to evaluate its safety and effectiveness.

Lupus Nephritis3-6 monthsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesNephrologyRheumatology

Psoriasis: [18F]Fluoride PET-CT Imaging Study

We are investigating if [18F]Fluoride PET-CT scans can detect early bone changes in psoriasis patients at risk for psoriatic arthritis. This study aims to see if this imaging method is effective for early detection.

Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyRheumatology

Lichen Simplex Chronicus: Dupilumab Injections

We are studying whether dupilumab injections can help reduce itching in adults with Lichen Simplex Chronicus who haven't found relief from other treatments. The trial will also look at how this treatment affects sleep and overall quality of life.

Neurodermatitis6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementAllergologyDermatology

Chronic Spontaneous Urticaria: BP11 vs. Xolair

We are comparing a new treatment, BP11, to Xolair for patients with chronic spontaneous urticaria who haven't responded to antihistamines. The goal is to see if BP11 is as effective and safe as Xolair.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Colorectal Cancer Prevention: Mesalamine for Lynch Syndrome

We are studying whether mesalamine can help prevent colorectal cancer in patients with Lynch syndrome. This trial compares mesalamine to a placebo to see if it reduces the occurrence of tumors.

Lynch Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyOncology

Chronic Low Back Pain: Melatonin Study

We are investigating whether melatonin can help reduce pain in patients with chronic low back pain. Participants will compare its effects to a placebo over six weeks.

Chronic Low Back Pain6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology